GDF2026 - Best Practices for Safety Assessment of Nitrosamines in Generic Drugs
U.S. Food and Drug Administration (FDA) · July 30, 2026
An FDA presenter gave a technical briefing on nitrosamine safety assessment for drugs, outlining mechanisms of carcinogenicity, FDA recommended approaches for establishing acceptable intake limits, common deficiencies in industry submissions, and next steps for harmonization and guidance.
AI-Generated Content: All content on this page was generated by AI to highlight key points from the meeting. For complete details and context, we recommend watching the full video. so we can fix them.
No transcript available.
No outline available for this source.
No related articles available for this source.
No highlights available for this source.
No claims available for this source.
No actions available for this source.
No topics available for this source.
No clarifying details available for this source.
No discussions available for this source.
No community relevance data available for this source.
No funding sources available for this source.
No speakers available for this source.
No transcript available for this source.